Literature DB >> 2834994

Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes.

A Tsuji1, H Sato, Y Kume, I Tamai, E Okezaki, O Nagata, H Kato.   

Abstract

The specific binding of 3H-labeled gamma-aminobutyric acid ([3H]GABA) to synaptic plasma membranes from rat brains was inhibited by various quinolonecarboxylic acid derivatives (quinolones), and these inhibitions were concentration dependent. The binding of [3H]muscimol to GABAA sites was also inhibited. These inhibitory potencies differed widely among the quinolones examined. The Dixon plots showed that a newly developed difluorinated quinolone, NY-198 [1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid hydrochloride], competitively inhibits the receptor bindings of [3H]GABA and [3H]muscimol. In conclusion, our findings suggest that the inhibition of GABA binding to receptors (including uptake sites) in the brain may be involved in the induction of epileptogenic neurotoxicities by quinolones.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834994      PMCID: PMC172133          DOI: 10.1128/AAC.32.2.190

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Assay of proteins in the presence of interfering materials.

Authors:  A Bensadoun; D Weinstein
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

2.  Physicochemical properties of beta-lactam antibiotics: oil-water distribution.

Authors:  A Tsuji; O Kubo; E Miyamoto; T Yamana
Journal:  J Pharm Sci       Date:  1977-12       Impact factor: 3.534

3.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Effect of penicillin on transmitter release from rat cortical tissue.

Authors:  T de Boer; J C Stoof; H van Duyn
Journal:  Brain Res       Date:  1980-06-16       Impact factor: 3.252

5.  Solubilization of gamma-aminobutyric acid receptor from rat brain.

Authors:  T Asano; N Ogasawara
Journal:  Life Sci       Date:  1980-04-07       Impact factor: 5.037

6.  Inhibitory effect of cephalosporins on gamma-aminobutyric acid receptor binding in rat synaptic membranes.

Authors:  S Hori; S Kurioka; M Matsuda; J Shimada
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Comparative stereostructure-activity studies on GABAA and GABAB receptor sites and GABA uptake using rat brain membrane preparations.

Authors:  E Falch; A Hedegaard; L Nielsen; B R Jensen; H Hjeds; P Krogsgaard-Larsen
Journal:  J Neurochem       Date:  1986-09       Impact factor: 5.372

8.  Brain receptor binding and lipophilic character of benzodiazepines.

Authors:  P A Borea; A Bonora
Journal:  Biochem Pharmacol       Date:  1983-02-15       Impact factor: 5.858

9.  Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system.

Authors:  S R Zukin; A B Young; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

10.  Inhibition of GABA and benzodiazepine receptor binding by penicillins.

Authors:  A Antoniadis; W E Müller; U Wollert
Journal:  Neurosci Lett       Date:  1980-07       Impact factor: 3.046

View more
  41 in total

1.  Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites.

Authors:  K Akahane; M Sekiguchi; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

3.  In vivo and in vitro toxicodynamic analyses of new quinolone-and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system.

Authors:  H Kita; H Matsuo; H Takanaga; J Kawakami; K Yamamoto; T Iga; M Naito; T Tsuruo; A Asanuma; K Yanagisawa; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Global and regional cerebral metabolic rate of 2-[18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid a receptor antagonist.

Authors:  E E Camargo; S Sostre; B Sadzot; I Shafique; Z Szabo; J M Links; R F Dannals; H N Wagner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

5.  The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure.

Authors:  Nimer Assy; Hana Gefen; Sorina Schlesinger; Osamah Hussein
Journal:  Dig Dis Sci       Date:  2007-12       Impact factor: 3.199

6.  Hippocampal activity in the presence of quinolones and fenbufen in vitro.

Authors:  W Dimpfel; M Spüler; A Dalhoff; W Hofmann; G Schlüter
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.

Authors:  Julien Brillault; Whocely Victor De Castro; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2009-10-12       Impact factor: 5.191

Review 8.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

9.  Reversible oral-facial dyskinesia in a patient receiving ciprofloxacin hydrochloride.

Authors:  P Pastor; E Moitinho; I Elizalde; I Cirera; E Tolosa
Journal:  J Neurol       Date:  1996-08       Impact factor: 4.849

10.  Effects of norfloxacin on the retina in rabbits.

Authors:  K Mochizuki; T Higashide; M Torisaki; Y Yamashita; M Komatsu; T Tanahashi; S Ohkubo; M Ogata; Y Ohnishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.